Journal of psychiatric research · 2025
Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression - A meta-analysis of randomized controllde trials.
СтатьяМетаанализПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Fenghua, Zhou Wei, Luo Haiyan, Su Dongyun, Dong Meng, Hu Yang, Lou Manxue, Li Gongbo, Zhang Yuqing
Аннотация
BACKGROUND: Depression is common as non-motor symptom in Parkinson's disease (PD). Evidence of antidepressants for PD with depression remain unclear. This meta-analysis examines the efficacy and tolerability of newer-generation antidepressants for PD with depression.
METHODS: Six international electronic databases (Cochrane, PubMed, Embase, Web of Science, CINAHL, and PsycINFO) and four Chinese electronic databases (CBM, CNKI, WanFang Data, and VIP) were systematically searched up to October 31, 2023. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (all-cause discontinuations). Secondary outcomes contained improvement in motor symptoms, change score of anxiety rating scales, improvement in cognitive function, and adverse events. This study was registered with PROSPERO, number CRD42020198364.
RESULT: A total of 11 trials with 713 participants were included. Newer-generation antidepressants significantly improved depressive symptoms (standardized mean differences (SMD) = -1.12 [-1.72; -0.52]), anxiety scores (SMD = -0.60 [-1.04; -0.17]). However, there was insufficient evidence in improving motor function in PD (SMD = -1.19 [-2.74; 0.36]) and the cognitive function (SMD = 0.57 [-0.33; 1.47]). Newer-generation antidepressants were associated with increased diminished sexual desire (RR = 2.34 [1.13; 4.86]) and insomnia (RR = 0.42 [0.22; 0.82]), but similar risk of all-cause discontinuations when compared with the control group (RR = 1.25 [0.85; 1.85]).
CONCLUSION: Newer-generation antidepressants appear to be beneficial and safe in treating depression in PD.
METHODS: Six international electronic databases (Cochrane, PubMed, Embase, Web of Science, CINAHL, and PsycINFO) and four Chinese electronic databases (CBM, CNKI, WanFang Data, and VIP) were systematically searched up to October 31, 2023. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (all-cause discontinuations). Secondary outcomes contained improvement in motor symptoms, change score of anxiety rating scales, improvement in cognitive function, and adverse events. This study was registered with PROSPERO, number CRD42020198364.
RESULT: A total of 11 trials with 713 participants were included. Newer-generation antidepressants significantly improved depressive symptoms (standardized mean differences (SMD) = -1.12 [-1.72; -0.52]), anxiety scores (SMD = -0.60 [-1.04; -0.17]). However, there was insufficient evidence in improving motor function in PD (SMD = -1.19 [-2.74; 0.36]) and the cognitive function (SMD = 0.57 [-0.33; 1.47]). Newer-generation antidepressants were associated with increased diminished sexual desire (RR = 2.34 [1.13; 4.86]) and insomnia (RR = 0.42 [0.22; 0.82]), but similar risk of all-cause discontinuations when compared with the control group (RR = 1.25 [0.85; 1.85]).
CONCLUSION: Newer-generation antidepressants appear to be beneficial and safe in treating depression in PD.